AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29655779 — intervention group
Group type: COMPARATOR
Intervention: Control muffin top (0.9 g TDF)
Number of subjects: 28
Study 28932087 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐urea breath test (UBT) with new test meal after 29 days of esomeprazole 40 mg
Number of subjects: 114
Study 28932087 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐urea breath test (UBT) with new test meal
Number of subjects: 114
Study 24576686 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration (within normal physiologic range)
Number of subjects: 16
Study 24576686 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin releasing hormone antagonist
Number of subjects: 16
Study 22133572 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil/folinic acid (FUFA)
Number of subjects: 168
Study 22133572 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil/folinic acid and irinotecan (FOLFIRI)
Number of subjects: 168
Study 21040559 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary stress treatment programme
Number of subjects: 63
Study 21040559 — intervention group
Group type: COMPARATOR
Intervention: Control group (one-hour consultation)
Number of subjects: 63
Study 17414590 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin + low-dose glimepiride + ADA diet + physical activity
Number of subjects: 70
Study 17414590 — intervention group
Group type: COMPARATOR
Intervention: metformin + ADA diet + physical activity
Number of subjects: 70
Study 17414590 — intervention group
Group type: COMPARATOR
Intervention: ADA diet + physical activity (no drugs)
Number of subjects: 70
Study 15723868 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-annual professional application of APF foam
Number of subjects: 392
Study 15723868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 11902986 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine (250 mg/d for 12 or 16 weeks)
Number of subjects: 151
Study 11902986 — intervention group
Group type: COMPARATOR
Intervention: itraconazole (400 mg/d for 1 week in every 4 for 12 or 16 weeks)
Number of subjects: 151
Study 11902986 — intervention group
Group type: COMPARATOR
Intervention: itraconazole
Number of subjects: 151
Study 11902986 — intervention group
Group type: EXPERIMENTAL
Intervention: terbinafine
Number of subjects: 151
Study 11902986 — intervention group
Group type: EXPERIMENTAL
Intervention: subsequent terbinafine treatment
Number of subjects: 151
Study 9835306 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDIT consumption questions 1 to 3
Number of subjects: 441
Study 8291967 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) therapy for shoulder muscles (supraspinatus and posterior deltoid), up to 6 hours a day for 6 weeks
Number of subjects: 26
Study 8291967 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 26
Study 2971913 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimentally induced stressor and personally relevant stressors during the premenstrual phase for group 1
Number of subjects: 39
Study 2971913 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimentally induced stressor and personally relevant stressors during the premenstrual phase for group 2
Number of subjects: 39
Study 30685298 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain/bran rye products (RP)
Number of subjects: 17
Study 30685298 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat products with added cellulose (WP)
Number of subjects: 17
Study 29429459 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii powder combined with azithromycin sequential therapy
Number of subjects: 88
Study 29429459 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment combined with azithromycin sequential therapy
Number of subjects: 88
Study 27813248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-polyphenol diet
Number of subjects: 24
Study 27813248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-ET diet
Number of subjects: 24
Study 27813248 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 24
Study 26164587 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O(2) administration
Number of subjects: 0
Study 26164587 — intervention group
Group type: COMPARATOR
Intervention: Sham O(2) administration
Number of subjects: 0
Study 26164587 — intervention group
Group type: COMPARATOR
Intervention: Sham O(2) after O(2) preconditioning
Number of subjects: 0
Study 22985547 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood management module
Number of subjects: 7763
Study 22985547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette counter
Number of subjects: 7763
Study 22985547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy guide
Number of subjects: 7763
Study 22985547 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 7763
Study 21575939 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg misoprostol inserted into the posterior vaginal fornix 3 hours before OH
Number of subjects: 150
Study 21575939 — intervention group
Group type: COMPARATOR
Intervention: Vaginal examination without misoprostol administration (control)
Number of subjects: 150
Study 17506119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (600 microg Cr(+3)) with biotin (2 mg)
Number of subjects: 447
Study 17506119 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 447
Study 17060120 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet supplemented with wheat-free oat products (GFD-oats)
Number of subjects: 116
Study 17060120 — intervention group
Group type: COMPARATOR
Intervention: Standard gluten-free diet (GFD-std)
Number of subjects: 116
Study 14631219 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Number of subjects: 62
Study 14631219 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic rebanding
Number of subjects: 62
Study 11149635 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood ante/retro cardioplegia
Number of subjects: 122
Study 11149635 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid ante/retro cardioplegia
Number of subjects: 122
Study 9186096 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.5 mg/ml for 3 1/2 minutes)
Number of subjects: 85
Study 9186096 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (50 mg/ml for 5 minutes)
Number of subjects: 85
Study 1357551 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (500 micrograms)
Number of subjects: 12
Study 1357551 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (500 micrograms) after 7 days
Number of subjects: 12
Study 1357551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3903157 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study 3903157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31182355 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous IUI
Number of subjects: 374
Study 31182355 — intervention group
Group type: COMPARATOR
Intervention: Regular IUI
Number of subjects: 374
Study 30409305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 250
Study 25685862 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual cues during retroactive interference paradigm
Number of subjects: 134
Study 25685862 — intervention group
Group type: COMPARATOR
Intervention: No contextual cues during retroactive interference paradigm
Number of subjects: 134
Study 25685862 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual cues for older adults with high cognitive functioning (Montreal Cognitive Assessment score ≥26)
Number of subjects: 134
Study 25685862 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual cues for older adults with low cognitive functioning (Montreal Cognitive Assessment score <26)
Number of subjects: 134
Study 23666269 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO‐SELF Pain Control Program
Number of subjects: 179
Study 23666269 — intervention group
Group type: COMPARATOR
Intervention: Control care
Number of subjects: 179
Study 21947440 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-assisted emotional disclosure
Number of subjects: 130
Study 21947440 — intervention group
Group type: COMPARATOR
Intervention: Education/support control
Number of subjects: 130
Study 20487038 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (155-195 U)
Number of subjects: 1384
Study 20487038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1384
Study 17989308 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart CSII
Number of subjects: 298
Study 17989308 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro CSII
Number of subjects: 298
Study 15667599 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg) inhalation
Number of subjects: 10
Study 15667599 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of caffeine
Number of subjects: 10
Study 11980359 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural networks (ANN)
Number of subjects: 99
Study 11980359 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (including unweighted application of criteria, regression coefficients, regression tree analysis)
Number of subjects: 99
Study 10613642 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural streptokinase (nSK) 1.5 million units, one-hour intravenous infusion
Number of subjects: 224
Study 10613642 — intervention group
Group type: COMPARATOR
Intervention: Recombinant streptokinase (rSK) 1.5 million units, one-hour intravenous infusion
Number of subjects: 224
Study 7844604 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion fluorouracil (5FU) 200 mg/m2/d via a Hick‐man line for 6 months with epirubicin 50 mg/m2 IV and cisplatin 60 mg/m2 IV every 3 weeks for eight courses
Number of subjects: 50
Study 7844604 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (control group)
Number of subjects: 50
Study 1742815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg.kg‐1 ketamine iv
Number of subjects: 20
Study 1742815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg‐1 ketamine iv
Number of subjects: 20
Study 6285279 — intervention group
Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 25
Study 6285279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31353126 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal Facilitating Techniques (VFTs); 10 individual sessions, twice a week
Number of subjects: 16
Study 31353126 — intervention group
Group type: COMPARATOR
Intervention: Manual Circumlaryngeal Therapy (MCT); 10 individual sessions, twice a week
Number of subjects: 16
Study 31353126 — intervention group
Group type: EXPERIMENTAL
Intervention: VFTs
Number of subjects: 16
Study 30791513 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical Cluster Environmental Protection Patrolling (CCEPP) game
Number of subjects: 0
Study 30791513 — intervention group
Group type: COMPARATOR
Intervention: Fixed route strategy
Number of subjects: 0
Study 30791513 — intervention group
Group type: COMPARATOR
Intervention: Purely randomized route strategy
Number of subjects: 0
Study 28796913 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 μg/g and betamethasone 0.5 mg/g foam
Number of subjects: 213
Study 28796913 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 μg/g and betamethasone 0.5 mg/g gel
Number of subjects: 213
Study 28796913 — intervention group
Group type: COMPARATOR
Intervention: Cal/BD foam and gel vs. latest topical treatment (LTT)
Number of subjects: 213
Study 28796913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cal/BD foam
Number of subjects: 213
Study 28796913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cal/BD gel
Number of subjects: 213
Study 25731215 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin needle
Number of subjects: 50
Study 25731215 — intervention group
Group type: COMPARATOR
Intervention: Standard needle
Number of subjects: 50
Study 23844488 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous poking K-wire fixation
Number of subjects: 135
Study 23844488 — intervention group
Group type: COMPARATOR
Intervention: Operative reduction (plate group)
Number of subjects: 135
Study 21044630 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioembolization
Number of subjects: 245
Study 21044630 — intervention group
Group type: COMPARATOR
Intervention: Chemoembolization
Number of subjects: 245
Study 19028932 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleic acid supplements
Number of subjects: 8
Study 19028932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16772625 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated load-distributing band (LDB) chest compression device
Number of subjects: 1071
Study 16772625 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 1071
Study 14759453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (heparin plus nafamostat, 0.2 mg/kg bolus followed by 2.0 mg/kg/h during cardiopulmonary bypass)
Number of subjects: 18
Study 14759453 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (heparin plus aprotinin, 2.0 x 10(4) KIU/kg)
Number of subjects: 18
Study 14759453 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 18
Study 14759453 — intervention group
Group type: COMPARATOR
Intervention: Nafamostat mesilate
Number of subjects: 18
Study 14759453 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin and Nafamostat
Number of subjects: 18
Study 11279651 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (low molecular weight heparin)
Number of subjects: 279
Study 11279651 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 279
Study 9642307 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 40
Study 8489752 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel releasing IUD (LNg IUD)
Number of subjects: 581
Study 8489752 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD and controls using no contraception
Number of subjects: 581
Study 3549083 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (cyclophosphamide, dipyridamole, and warfarin)
Number of subjects: 52
Study 3549083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 52
Study 3549083 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (cyclophosphamide, dipyridamole, and warfarin) among patients with IgA nephritis (n = 27)
Number of subjects: 52
Study 3549083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) among patients with IgA nephritis (n = 21)
Number of subjects: 52
Study 3549083 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (cyclophosphamide, dipyridamole, and warfarin) among matched pairs (n = 23)
Number of subjects: 52
Study 3549083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment) among matched pairs (n = 23)
Number of subjects: 52
Study 30945105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (30 µg)
Number of subjects: 80
Study 30945105 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 29665405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 930
Study 29665405 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I indication for CRT
Number of subjects: 930
Study 27420318 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 muscle groups PMR
Number of subjects: 26
Study 27420318 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 muscle groups PMR
Number of subjects: 26
Study 27420318 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 23632352 — intervention group
Group type: EXPERIMENTAL
Intervention: BIO-THREE probiotics
Number of subjects: 159
Study 22699827 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat robotic-assisted training
Number of subjects: 80
Study 22699827 — intervention group
Group type: COMPARATOR
Intervention: Overground therapy
Number of subjects: 80
Study 20846058 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end approximation
Number of subjects: 128
Study 20846058 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap technique
Number of subjects: 128
Study 17586139 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of mifepristone once every 14 days for six cycles
Number of subjects: 50
Study 17586139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15680804 — intervention group
Group type: EXPERIMENTAL
Intervention: Early low-dose steroid therapy (methylprednisolone, 2 mg/kg loading dose followed by 2 mg/kg per day)
Number of subjects: 20
Study 15680804 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 20
Study 12075915 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive disclosure
Number of subjects: 30
Study 12075915 — intervention group
Group type: COMPARATOR
Intervention: Non-disclosure
Number of subjects: 30
Study 10605950 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose wine group
Number of subjects: 9
Study 10605950 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose wine group
Number of subjects: 9
Study 10605950 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study 7785460 — intervention group
Group type: EXPERIMENTAL
Intervention: UroPhos-K
Number of subjects: 21
Study 7785460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2228846 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination (SDD) with initial systemic cefotaxime (500 mg tid for 5 days)
Number of subjects: 0
Study 2228846 — intervention group
Group type: COMPARATOR
Intervention: Control group A (antibiotics that disturb colonization resistance)
Number of subjects: 0
Study 2228846 — intervention group
Group type: COMPARATOR
Intervention: Control group B (antibiotics not affecting colonization resistance)
Number of subjects: 0
Study 356244 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren (diclofenac sodium) 50 mg
Number of subjects: 60
Study 356244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31662998 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery (G2)
Number of subjects: 65
Study 31662998 — intervention group
Group type: COMPARATOR
Intervention: Drill (G1)
Number of subjects: 65
Study 27856955 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 155
Study 25387477 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg every 4 weeks
Number of subjects: 356
Study 25387477 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg after dose adjustment
Number of subjects: 356
Study 25387477 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 356
Study 23291315 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate and uninterrupted skin-to-skin contact at birth
Number of subjects: 0
Study 23291315 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooming-in during postpartum
Number of subjects: 0
Study 23291315 — intervention group
Group type: COMPARATOR
Intervention: Separation and swaddling at birth
Number of subjects: 0
Study 21510319 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg itopride following a test meal (200 kcal per 200mL, containing 100mg 13C acetate)
Number of subjects: 8
Study 21510319 — intervention group
Group type: COMPARATOR
Intervention: Test meal alone
Number of subjects: 8
Study 19698172 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AS&AQ)
Number of subjects: 11700
Study 19698172 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 11700
Study 19698172 — intervention group
Group type: COMPARATOR
Intervention: Artesunate plus sulfadoxine-pyrimethamine (AS+SP)
Number of subjects: 11700
Study 19698172 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 11700
Study 16076944 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological recombinant methionyl human leptin
Number of subjects: 20
Study 12233104 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin treatment in group A (sick sinus syndrome with pacemaker)
Number of subjects: 641
Study 12233104 — intervention group
Group type: COMPARATOR
Intervention: Warfarin treatment in group B (atrial fibrillation without pacemaker)
Number of subjects: 641
Study 12233104 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin dosage in group A
Number of subjects: 641
Study 12233104 — intervention group
Group type: COMPARATOR
Intervention: Warfarin dosage in group B
Number of subjects: 641
Study 12233104 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-INR and TT measurements
Number of subjects: 641
Study 10404735 — intervention group
Group type: EXPERIMENTAL
Intervention: Normotensives
Number of subjects: 51
Study 10404735 — intervention group
Group type: COMPARATOR
Intervention: Hypertensives
Number of subjects: 51
Study 10404735 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 51
Study 7590502 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g fish oil
Number of subjects: 32
Study 7590502 — intervention group
Group type: COMPARATOR
Intervention: 3 g corn oil (placebo)
Number of subjects: 32
Study 2138595 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone 0.4 mg (i.m.)
Number of subjects: 15
Study 2138595 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone 4 mg (i.v.)
Number of subjects: 15
Study 2138595 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 15
Study 2138595 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone (both doses)
Number of subjects: 15
Study 6766833 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital 60 mg orally
Number of subjects: 6
Study 6766833 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid 250 mg orally twice daily for 14 days + Phenobarbital 60 mg orally on day 4
Number of subjects: 6